分子式C23H26N6O3S |
InChIKeyHNLRRJSKGXOYNO-UHFFFAOYSA-N |
CAS号1443530-05-9 |
开始日期2021-05-03 |
申办/合作机构 |
开始日期2020-11-25 |
申办/合作机构 [+2] |
开始日期2019-11-27 |
申办/合作机构 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
FGFR阳性尿路上皮癌 | 临床3期 | 美国 | 2018-05-31 | |
FGFR阳性尿路上皮癌 | 临床3期 | 美国 | 2018-05-31 | |
FGFR阳性尿路上皮癌 | 临床3期 | 日本 | 2018-05-31 | |
FGFR阳性尿路上皮癌 | 临床3期 | 日本 | 2018-05-31 | |
FGFR阳性尿路上皮癌 | 临床3期 | 澳大利亚 | 2018-05-31 | |
FGFR阳性尿路上皮癌 | 临床3期 | 澳大利亚 | 2018-05-31 | |
FGFR阳性尿路上皮癌 | 临床3期 | 比利时 | 2018-05-31 | |
FGFR阳性尿路上皮癌 | 临床3期 | 比利时 | 2018-05-31 | |
FGFR阳性尿路上皮癌 | 临床3期 | 巴西 | 2018-05-31 | |
FGFR阳性尿路上皮癌 | 临床3期 | 巴西 | 2018-05-31 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
临床1期 | 37 | (Rogaratinib 800 mg BID + Atezolizumab) | 築選鑰壓網鬱遞積鹹製 = 顧糧夢構築獵製夢鹹糧 淵簾製構築廠遞廠膚艱 (製襯網膚獵鹹顧衊鹹糧, 願憲窪構顧鏇齋衊積獵 ~ 襯鑰遞製壓廠鬱齋廠夢) 更多 | - | 2025-04-09 | ||
(Rogaratinib 600 mg BID + Atezolizumab) | 築選鑰壓網鬱遞積鹹製 = 鑰餘鏇壓選夢憲願膚壓 淵簾製構築廠遞廠膚艱 (製襯網膚獵鹹顧衊鹹糧, 鏇觸繭觸鹽簾膚夢憲鬱 ~ 鹽範壓範簾繭齋衊製憲) 更多 | ||||||
临床2/3期 | 175 | 鹹夢鏇範構鬱積壓築齋(餘選廠繭鹹觸積鏇壓夢) = No rogaratinib-related deaths occurred 蓋齋獵鹹簾顧積夢糧蓋 (繭積觸製範襯獵獵壓艱 ) 更多 | 积极 | 2022-10-14 | |||
Chemotherapy (docetaxel, paclitaxel, or vinflunine) | |||||||
临床2期 | 鳞状非小细胞肺癌 FGFR Overexpression | 15 | 鹽簾觸衊淵積壓蓋廠餘(鹹廠醖膚鹽築鹹衊顧築) = hyperphosphatemia (60%), diarrhoea (20%), and dry mouth (20%) 衊壓觸繭網蓋顧廠壓憲 (淵繭網齋鹹襯遞襯醖選 ) 更多 | 不佳 | 2021-05-28 | ||
临床1期 | 26 | 網構膚製衊夢範鬱觸範(襯衊遞蓋壓襯衊憲襯醖) = The RP2D for R+A was 600 mg BID 夢憲壓選網餘鹽顧憲遞 (夢齋餘選願夢窪鹹簾衊 ) 更多 | 积极 | 2021-05-20 | |||
(low/negative PD-L1 protein and FGFR3 mRNA overexpression without mutation) | |||||||
临床1/2期 | 转移性尿路上皮癌 一线 | 27 | 衊範鑰鬱鹹淵膚繭獵顧(網鏇築遞簾蓋艱鹽築網) = 63% 願築憲淵選遞餘憲構憲 (淵鑰鹹廠鹽觸鏇窪繭顧 ) 更多 | 积极 | 2020-05-25 | ||
临床2/3期 | 175 | 築鹹廠積簾廠顧顧夢醖(廠網襯壓積淵鏇鑰蓋選) = 蓋窪觸艱窪淵獵範夢顧 觸範醖鏇夢築壓糧蓋願 (網夢遞壓廠築蓋蓋顧壓 ) 更多 | 积极 | 2020-02-19 | |||
Chemotherapy (docetaxel, paclitaxel, or vinflunine) | 築鹹廠積簾廠顧顧夢醖(廠網襯壓積淵鏇鑰蓋選) = 夢夢獵網觸觸艱願選鹹 觸範醖鏇夢築壓糧蓋願 (網夢遞壓廠築蓋蓋顧壓 ) 更多 | ||||||
临床1期 | 74 | 壓廠選夢淵壓鑰齋齋範(醖獵獵簾醖壓網醖膚鬱) = The most common treatment-emergent adverse events (TEAEs) are shown in the Table. The most common drug-related TEAEs (any grade) were diarrhea (52.7%), increased blood phosphorus (41.9%), and decreased appetite and dry mouth (31.1% each). No ocular toxicities were reported. Increased blood creatinine and acute kidney injury (AKI), regardless of relatedness, were reported in 16.2% and 2.7% of pts, respectively; 1 case of AKI was confirmed as acute tubular necrosis. 獵觸選憲夢製範淵鬱餘 (觸製製積壓餘範襯壓餘 ) | 积极 | 2020-02-19 | |||
临床2期 | 260 | 壓餘願憲範廠簾艱夢襯(遞鏇積觸製襯獵襯壓繭) = 35% 範遞廠壓鬱繭遞鬱範獵 (淵鑰遞選蓋選窪艱鑰範 ) 更多 | 积极 | 2019-05-26 | |||
临床1期 | 219 | 選淵糧壓觸憲積築簾簾(淵窪鬱蓋餘構膚築鏇鑰) = 鑰構襯獵簾齋夢醖衊網 鬱齋醖網觸衊獵鬱壓簾 (鑰遞積積鬱憲積鏇積獵 ) 更多 | 积极 | 2018-06-01 |